RTI Compositions Targeting L1-Driven Age-Associated Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for better treatment and prevention of age-related inflammation and disorders, as the mechanisms underlying age-related inflammation and its role in aging are not fully understood, and existing treatments for chronic degenerative diseases associated with inflammation are limited.

Innovation Solution

The use of reverse transcriptase inhibitors (RTIs), specifically censavudine or elvucitabine, to inhibit the activity of retrotransposable elements (RTEs) such as L1, which are upregulated during cellular senescence and trigger a type-I interferon (IFN-I) response, thereby reducing age-associated inflammation and its related disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If reverse transcriptase inhibitors are used to treat age-associated inflammation, then the harmful effects of retrotransposable element activation are reduced, but the understanding and treatment of chronic degenerative diseases remain limited

Engineering Contradiction:

Improveage-associated inflammationVSAvoidtreatment effectiveness for chronic degenerative diseases

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies this principle by converting the harmful activation of retrotransposable elements (which causes inflammation) into a targetable mechanism. By identifying that RTE activation drives age-associated inflammation, the invention uses RTIs to block this harmful pathway, thereby converting the understanding of a detrimental process into a therapeutic opportunity for treating chronic degenerative diseases

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent employs parameter changes by modifying the inflammatory response parameters through RTI administration. The treatment changes the state of the system by inhibiting reverse transcriptase activity, which downregulates IFN-I activation and reduces the pro-inflammatory state, thereby altering the pathological parameters of age-associated diseases

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If RTIs are administered to inhibit L1 reverse transcriptase activity, then IFN-I activation is downregulated, but the mechanisms controlling age-related inflammation are not fully understood

Engineering Contradiction:

Improvetreatment administrationVSAvoidmechanism understanding

Core Design Contradiction:

Ease of operationVSDifficulty of detecting and measuring

Solution Approach 1:

The patent uses reverse transcriptase inhibitors as an intermediary substance to study and treat the relationship between RTE activation and inflammation. The RTI acts as a mediator that blocks the reverse transcriptase enzyme, allowing researchers to observe the downstream effects on IFN-I activation and inflammatory responses, thereby facilitating both treatment and mechanistic understanding

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If existing treatments are used for chronic degenerative diseases, then current standard care is provided, but progress in understanding and treating age-related inflammation is limited

Engineering Contradiction:

Improvecurrent treatment standardVSAvoidresearch progress

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies preliminary action by establishing a new therapeutic approach using RTIs before conventional treatments can be optimized for age-associated inflammation. By identifying the RTE-IFN-I-inflammatory pathway as a target, the invention introduces a novel mechanism-based treatment that precedes and potentially enhances the effectiveness of current standard care for chronic degenerative diseases

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

RTIs effectively downregulate IFN-I activation and reduce age-associated inflammation, potentially delaying or reversing the progression of diseases like Alzheimer's disease and ALS by targeting L1 reverse transcriptase activity, as demonstrated by empirical observations and comparative dose-response assays.

Implementation Method 1

the RTI comprises censavudine or elvucitabine... inhibit the activity of retrotransposable elements (RTEs) such as L1... targeting L1 reverse transcriptase activity

Methodology Applied

Scientific EffectReverse transcriptase inhibition: Enzyme

Data Source

PatentEP3914604B1Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders

Publication Date: 2026.03.04 BROWN UNIVERSITY

Figure 1a~1e
Figure 2a~2f
Figure 2g~2h

AI summary

Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one reverse transcriptase inhibitor (RTI).